Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 11;101(6):e28814.
doi: 10.1097/MD.0000000000028814.

Expression and prognostic impact of CD49b in human lung cancer

Anna Tirilomi  1 , Omar Elakad  2 , Sha Yao  2 , Yuchan Li  2 , Marc Hinterthaner  1 , Bernhard C Danner  1 , Philipp Ströbel  2 , Theodor Tirilomis  1 , Hanibal Bohnenberger  2 , Alexander von Hammerstein-Equord  1
Affiliations

Expression and prognostic impact of CD49b in human lung cancer

Anna Tirilomi et al. Medicine (Baltimore). .

Abstract

Lung cancer remains the worldwide leading cause of cancer-related death. Currently, prognostic biomarkers for the detection and stratification of lung cancer are being investigated for clinical use. The surface protein cluster of differentiation 49b (CD49b) plays an important role in promoting cell proliferation and invasion in different tumor entities and blocking CD49b improved the tumor immune response. Overexpression of CD49b has been associated with unfavorable survival rates in several malignant tumor entities, such as prostate cancer, gastric cancer and colon cancer. Therefore, we aimed to analyze the protein expression of CD49b in patients with different types of lung cancer and additionally to identify the influence of CD49b on clinicopathological characteristics and overall survival.Expression levels of CD49b were retrospective analyzed by immunohistochemistry in 92 cases of pulmonary adenocarcinoma (AC), 85 cases of squamous cell lung carcinoma (SQCLC) and 32 cases of small cell lung cancer (SCLC) and correlated with clinicopathological characteristics and patients' overall survival.A strong expression of CD49b was most seen in SQCLC (78%), followed by AC (48%) and SCLC (9%). All patients combined, strong expression of CD49b correlated significantly with poorer overall survival. However, an increased expression of CD49b correlated significantly with a poorer survival rate only in SQCLC. In AC and SCLC, no significant correlation could be demonstrated in this regard.In our study, CD49b expression was associated with poor overall survival in patients with SQCLC. Accordingly, CD49b could serve as a new prognostic biomarker and, moreover, be a potential new drug target in SQCLC.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Representative immunohistochemical staining with negative (staining score 0), weakly positive (staining score 1) or strongly positive (staining score 2) immunostaining of CD49b in squamous cell lung cancer samples. Scale bar: 100 μm.
Figure 2
Figure 2
Protein expression of CD49b sorted by entity and categorized as negative, weakly positive, and strongly positive expression. AC = adenocarcinoma, SCLC = small cell lung cancer, SQCLC = squamous cell lung cancer.
Figure 3
Figure 3
Kaplan–Meier analysis of OS in all patients (A), in patients with SQCLC (B), AC (C) and SCLC (D). The P value is from a log-rank test. AC = adenocarcinoma, OS = overall survival, SCLC = small cell lung cancer, SQCLC = squamous cell lung cancer.
See this image and copyright information in PMC

References

    1. Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med 2020;41:01–24. - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, et al. . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. - PubMed
    1. Rahib L, Smith BD, Aizenberg R, et al. . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913–21. - PubMed
    1. Quante AS, Ming C, Rottmann M, Engel J, et al. . Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med 2016;5:2649–56. - PMC - PubMed
    1. Wahbah M, Boroumand N, Castro C, et al. . Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol 2007;11:89–96. - PubMed

MeSH terms